Completed PHASE2 INTERVENTIONAL NCT00273039

A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects With Social Anxiety Disorder

Sponsor: GlaxoSmithKline

Conditions Anxiety Disorders Social Anxiety Disorder

Interventions paroxetine

Updated 7 times since 2017 Last updated: Oct 24, 2016 Started: Aug 31, 2005 Primary completion: Sep 30, 2006 Completion: Sep 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Anxiety Disorders and Social Anxiety Disorder and is currently completed. GlaxoSmithKline leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beverly Hills, United States , Buenos Aires, Argentina , Burbank, United States , Córdoba, Argentina , Edmonton, Canada , Jacksonville, United States , Kelowna, Canada , La Plata/Buenos Aires, Argentina , Lake Jackson, United States , Mexico City, Mexico and 14 more locations